

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

Institutional Biosafety Committee Meeting minutes

Meeting Attendance:

- Members in attendance:
 - Elena Demireva
 - Dave Morgan
 - Jonathan Hardy
 - Sarah Roosa
 - Raj Kulkarni
 - Jamie Willard-Smith
 - Michael Bachmann
 - Guo-Qing Song
- Members not in attendance:
 - Jan Patterson Samson
 - Carrie Anglewicz
 - Carolina de Aguiar Ferreira
 - Andras Komaromy
 - Simon Petersen-Jones
- Others in attendance:
 - Chris Colvin
 - Luis Ochoa Carrera

Call to order:

Elena Demireva

Roll call:

Chris Colvin

Discussion of the agenda:

- Approved

Discussion of minutes:

- Approved: Edit Risk Group for Safety0001375

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

Registration review:

Study Info

Safety0001360: [REDACTED]

Amplification of cGAS and STING gene sequences

Training: Complete for all members listed

NIH III D-4-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Bacteria
 - 1: Update to BSL-1 for C. elegans unless needed for your strain.
- rDNA Usage
 - 10: Add Notify GRRC security to Immediate Notification.
- Exposure Assessment
 - 3: Add Autoclave number and location.
 - 3: Update eye wash flush date.

Study Info

Safety0001372: [REDACTED]

Role of AHR in metabolism

Training: Complete for all members listed

NIH III-D-4, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Cells
 - 5e: Add Primary Hepatocytes to flow addendum.
- rDNA usage
 - 8: Address the three points in the question in terms of probability and consequences. It is important to be aware and acknowledge potential hazards, and risks that do exist with the use of AAV.
- rDNA Work Description
 - 7: Change to Yes and fill out regarding the Cre-LoxP system.
- Exposure Assessment
 - 3: Add Centrifuge lids with aerosol containment to engineering controls.
 - 3: Update eye wash flush date.
 - 4: If using sharps to deliver virus add and include on sharps forms.
 - 5: Include 10% bleach for 10 min contact time.

Study Info

Safety0001387: [REDACTED]

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

High Resolution Imaging of Cortical Activity During Memory Formation and Recall

Training: Complete for all members listed

NIH III D-4-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 8: Address the three points in the question in terms of probability and consequences. It is important to be aware and acknowledge potential hazards, and risks that do exist with the use of AAV.
 - 9: Add, volunteer students can go to Olin center or own doctor.
- Exposure Assessment
 - 3: Add Centrifuge lids with aerosol containment to engineering controls
 - 3: Update eye wash flush date.
 - 4: Include sharps used with AAV delivery. Include these sharps on the annual sharps forms on the Supporting Documents page.
- Supporting Documents
 - Include Annual Sharps review form for sharps used with infectious material.

Study Info

Safety0001390: [REDACTED]

Ocular Therapy

Training: Complete for all members listed

NIH III D-4-b, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 6: List genus of viral vector.
 - 8: Remove last “very low risk” statement.
- Exposure Assessment
 - 3: Update eye wash flush date.
 - 4: Include sharps used for AAV delivery, include these on the annual sharps form on the supporting documents page.
- Supporting Documents
 - Include Annual Sharps review form for sharps used with infectious material.

Study Info

Safety0001397: [REDACTED]

[REDACTED]-Light and mood 2025

Training: Complete for all members listed

NIH III D-1-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

- Virus
 - 1: Update source of material ([REDACTED] is no longer with MSU, update to new affiliation).
- rDNA Usage
 - 2: Update NIH category to III-D-4 and proper subcategory.
 - 8: Address the three points in the question in terms of probability and consequences. It is important to be aware and acknowledge potential hazards, and risks that do exist with the use of AAV.
- rDNA Work Description
 - 1: Change to Yes, include information for viral vector.
 - 6: Add Genus
- Exposure Assessment
 - 1: Update to address risks of AAV and potential exposure to AAV.
 - 3: Add Centrifuge lids with aerosol containment to engineering controls
 - 3: Update eye wash flush date.

Study Info

Safety0001405: [REDACTED]

Neuronal Signaling

Training: Complete for all members listed

NIH III 4-c-2, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 2: Remove category III-D-1 and III-D-3, add III-D-4 and proper subcategory.
 - 4e: Discuss features of the viral vector.
 - 8: Remove “No risk is noted.” Instead, address the three points in the question in terms of probability and consequences. It is important to be aware and acknowledge potential hazards, and risks that do exist with the use of AAV.
- rDNA Work Description
 - 6: Add Genus
- Exposure Assessment
 - 1. Change Adenovirus to AAV
 - 3: Add Centrifuge lids with aerosol containment to engineering controls
 - 3: Update eye wash flush date.
- Supporting Documents
 - Add Sharps review form for sharps used for AAV delivery.

Study Info

Safety0001406: [REDACTED]

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

██████-Circadian Rhythms in Plants

Training: Complete for all members listed

NIH III E-2-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary: Remove last statement: “registration states generating transgenic plants
- rDNA Usage
 - 7: Change to No if just using for selection.
- rDNA Work Description
 - 1: Include references or links for purchased materials or refer to supporting documents attached.
- Exposure Assessment
 - 1: Address potential consequences of environmental release of all transgenic species and inserts used not just luciferase and potato.
 - 3: Update eye wash flush date.

Study Info

Safety0001407: ██████████

Quasiorganelle Therapy for Canine Histiocytic Sarcoma

Training: Complete for all members listed

NIH III D-4-a, RG-2, BSL-2+

This registration has been approved with edits. Jonathan Hardy abstained from the vote. The PI has been asked to clarify the following:

- Virus
 - The IBC recommends switching to a 3rd or later generation Lentiviral vector for increased safety features.
- rDNA Usage
 - 3b: Add missing transposase and transposons inserts.
 - 3c: The activation of innate immunity might cause eventual autoimmune response.
 - 4e: Address the safety features of the Lentiviral vector.
 - 5a: Listeria is a host not a recipient. Remove eukaryotic cell lines.
- rDNA Work Description
 - 4: Yes, for VSV pseudotyping.
 - 7: Change to Yes, add information for transposon use.

Study Info

Safety0001408: ██████████

AAV Use

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

Training: Complete for all members listed

NIH III D-4, RG-1, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 8: Address the three points in the question in terms of probability and consequences. It is important to be aware and acknowledge potential hazards, and risks that do exist with the use of AAV. Remove statement risks are quite low.
- rDNA Work Description
 - 5: Change to Yes
 - 6: Change to Yes
- Exposure Assessment
 - 3: Add Centrifuge lids with aerosol containment to engineering controls.
 - 3: Update BSC number
 - 3: Update eye wash flush date
- Supporting Documents
 - Add Sharps review form for sharps used for AAV delivery. Attached sharps documents are currently blank.

Study Info

Safety0001414: [REDACTED]

Modeling gynecological disease 3

Training: Complete for all members listed

NIH III D-4-c-2, RG-1, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Information
 - 3: Remove duplicate “We” in 3rd sentence.
- Cells
 - 1: Update MA10 cells to BSL-2. All human cell lines are BSL-2 at MSU.
- Virus
 - 1: Update Lentivirus to just 3rd generation if only using. Downgrade to BSL-2 if not using 2nd generation.
 - The IBC recommends to switching to a 3rd or later generation Lentiviral vector for increased safety features.
- rDNA Usage
 - 4a: Add plasmids.
 - 5a: Remove last sentence “Primary human/primate cells...”.

Institutional Biosafety Committee Meeting

12/9/2025

10:30am-12:00pm

Zoom Virtual Meeting

- 8: Remove very low risk of virus statement. Use same statement for addressing points for each viral vector.
- rDNA Work Description
 - 5: Missing Host range. Remove helper virus language and replace with packaging system or be more inclusive of host packaging system.
- Exposure Assessment
 - 1: Remove language of “no significant consequences” statement. Revise statement, for example, Lenti will immortalize an exposed cell, don’t minimize the risks as low. It is important to be aware and acknowledge the potential hazards.
 - 1: BBP, remove low risk statement.
 - 3: Update eyewash flush date.
- Supporting Documents
 - Include safer sharps devices in form, update justification for glass pipettes, can consider to switching to plastic if used for aspiration.

New Items:

- N/A

Previous Submissions:

- None

Next Meeting:

January 13, 2026 1:30pm via zoom